VNDAVanda Pharmaceuticals Inc.

CSNasdaq (XNAS)·USD

Identity

Security key: 23397
Ticker: VNDA
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2006-04-12
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: VNDA

Detail

Enriched 2026-08-14 20:47

Market cap: $313,801,345.53
Shares outstanding (class): 60,462,687
Shares outstanding (weighted): 60,462,687
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 533
Location: WASHINGTON, DC
Homepage: https://www.vandapharma.com
Description: Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Market cap and share counts drift.

Funds holding this security

88 funds · 88 positions · $59.29M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS	VTI	$12.17M	0.00%	1,761,840 NS	FIGI
State Street(R) SPDR(R) S&P(R) Biotech ETF SPDR SERIES TRUST	XBI	$11.77M	0.16%	1,704,031 NS	FIGI
iShares Russell 2000 ETF iShares Trust	IWM	$9.45M	0.01%	1,368,159 NS	FIGI
VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS	VXF	$4.59M	0.01%	664,743 NS	FIGI
iShares Russell 2000 Value ETF iShares Trust	IWN	$3.27M	0.03%	473,447 NS	FIGI
iShares Biotechnology ETF iShares Trust	IBB	$2.80M	0.03%	405,038 NS	FIGI
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND VANGUARD HORIZON FUNDS	—	$1.38M	0.06%	199,474 NS	FIGI
JPMorgan Small Cap Value Fund JPMorgan Trust II	—	$1.08M	0.09%	156,006 NS	FIGI
iShares Micro-Cap ETF iShares Trust	IWC	$969.9K	0.08%	140,359 NS	FIGI
SMALL CAP EQUITY FUND GuideStone Funds	—	$805.8K	0.10%	116,609 NS	FIGI
iShares Core S&P Total U.S. Stock Market ETF iShares Trust	ITOT	$795.6K	0.00%	115,135 NS	FIGI
NVIT Multi-Manager Small Company Fund Nationwide Variable Insurance Trust	—	$677.2K	0.19%	98,004 NS	FIGI
Master Small Cap Index Series Quantitative Master Series LLC	—	$645.4K	0.01%	93,404 NS	FIGI
BlackRock Advantage SMID Cap Fund, Inc. BlackRock Advantage SMID Cap Fund, Inc.	—	$633.7K	0.08%	91,708 NS	FIGI
NVIT Small Cap Value Fund Nationwide Variable Insurance Trust	—	$603.0K	0.32%	87,265 NS	FIGI

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

Funds holding this security

Identifiers

master.security_identifier

TICKERVNDA
FIGI_COMPOSITEBBG000HT5MG6
FIGI_SHARE_CLASSBBG001SP95N5
CIK0001347178
ISINUS9216591084
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: Vanda Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies, classified under pharmaceutical preparations.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.